Literature DB >> 7840513

Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years.

B Lindahl1, R Willén.   

Abstract

The treatment of patients with endometrial hyperplasia differs widely, ranging from immediate hysterectomy to no treatment or follow-up at all. This is due to the fact that a vital question has not been answered, namely: is endometrial hyperplasia a predecessor to carcinoma or not? In order to investigate whether endometrial hyperplasia is a premalignant state we have followed up 246 patients with abrasio only for 5 years. We found that there was no higher risk of CGH and adenomatous hyperplasia developing into a carcinomatous state than in normal cases. We found it possible to follow up these patients with abrasio only as scheduled. The very few patients developing carcinoma did so already at the first control after 3 months. Among atypical endometrial hyperplasias there was an increased risk of developing endometrial carcinoma. We could divide these patients into two groups: one with very severe atypia so close to carcinoma that an immediate hysterectomy was recommended. Nine out of 12 had already developed carcinoma at the time of the operation. In another group of 21 patients followed with abrasio only, 2 had developed carcinoma at the first control. This means that among 368 patients with endometrial hyperplasia followed-up with abrasio for 2 years, 13 were found to have carcinoma. Twelve patients with very severe atypia were recommended to have an operation and 9 were found to have cancer. Among the other 356 patients, 4 were found to have cancer at the first control (2 with an initial diagnosis of CGH and 2 with atypical hyperplasia).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840513

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

2.  Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Authors:  Susan D Reed; Katherine M Newton; Rochelle L Garcia; Kimberly H Allison; Lynda F Voigt; C Diana Jordan; Meira Epplein; Elizabeth Swisher; Kristen Upson; Kelly J Ehrlich; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

3.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

4.  Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

5.  Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Authors:  J V Lacey; O B Ioffe; B M Ronnett; B B Rush; D A Richesson; N Chatterjee; B Langholz; A G Glass; M E Sherman
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.